Evaluation of the Invasive Potential of Superficial Bladder Cancer by Adenosine Triphosphate Measurement

Koiso, Kenkichi; Nemoto, Ryosuke; Ohtani, Mikinobu; Uchida, Katsuo; Shimazui, Toru; Noguchi, Ryosuke; Hattori, Kohshi; Miyanaga, Naoto; Shiraiwa, Hiroshi; Iwasaki, A

doi:10.1159/000282120

Cited by 5 publications

(3 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TEM detected an increase in both apoptotic bodies and necrosis in treated tumours [33]. There is high correlation between adenine nucleotide content and bladder tumour progression [509]. There was upregulation of P2Y receptors in T24, a transitional cell carcinoma cell line [510].…”

Section: Bladder Cancermentioning

confidence: 99%

Purinergic signalling and cancer

Burnstock

Virgilio

2013

Purinergic Signalling

272

265

View full text Add to dashboard Cite

Receptors for extracellular nucleotides are widely expressed by mammalian cells. They mediate a large array of responses ranging from growth stimulation to apoptosis, from chemotaxis to cell differentiation and from nociception to cytokine release, as well as neurotransmission. Pharma industry is involved in the development and clinical testing of drugs selectively targeting the different P1 nucleoside and P2 nucleotide receptor subtypes. As described in detail in the present review, P2 receptors are expressed by all tumours, in some cases to a very high level. Activation or inhibition of selected P2 receptor subtypes brings about cancer cell death or growth inhibition. The field has been largely neglected by current research in oncology, yet the evidence presented in this review, most of which is based on in vitro studies, although with a limited amount from in vivo experiments and human studies, warrants further efforts to explore the therapeutic potential of purinoceptor targeting in cancer.

show abstract

Section: Bladder Cancermentioning

confidence: 99%

Purinergic signalling and cancer

Burnstock

Virgilio

2013

Purinergic Signalling

272

265

View full text Add to dashboard Cite

show abstract

“…That is, AMPK activation advantages tumor cell growth and proliferation. In addition, the measurement of this nucleotide has exhibited a correlation between AMP concentration and tumor progression, revealing high AMP levels in BCa cases that became invasive and/or metastatic [ 66 ]. The metabolites CDCA and GCDCA are a part of the bile acids group synthesized from cholesterol in the liver.…”

Section: Resultsmentioning

confidence: 99%

Unmasking the Metabolite Signature of Bladder Cancer: A Systematic Review

Pereira,

Domingues,

Vitorino

et al. 2024

IJMS

View full text Add to dashboard Cite

Bladder cancer (BCa) research relying on Omics approaches has increased over the last few decades, improving the understanding of BCa pathology and contributing to a better molecular classification of BCa subtypes. To gain further insight into the molecular profile underlying the development of BCa, a systematic literature search was performed in PubMed until November 2023, following the PRISMA guidelines. This search enabled the identification of 25 experimental studies using mass spectrometry or nuclear magnetic resonance-based approaches to characterize the metabolite signature associated with BCa. A total of 1562 metabolites were identified to be altered by BCa in different types of samples. Urine samples displayed a higher likelihood of containing metabolites that are also present in bladder tumor tissue and cell line cultures. The data from these comparisons suggest that increased concentrations of L-isoleucine, L-carnitine, oleamide, palmitamide, arachidonic acid and glycoursodeoxycholic acid and decreased content of deoxycytidine, 5-aminolevulinic acid and pantothenic acid should be considered components of a BCa metabolome signature. Overall, molecular profiling of biological samples by metabolomics is a promising approach to identifying potential biomarkers for early diagnosis of different BCa subtypes. However, future studies are needed to understand its biological significance in the context of BCa and to validate its clinical application.

show abstract

“…There is high correlation between adenine nucleotide content and bladder tumour progression (Koiso et al . ). There was upregulation of P2Y receptors in T24, a transitional cell carcinoma cell line (Artim et al .…”

Section: Cancermentioning

confidence: 97%

Purinergic signalling in the lower urinary tract

Burnstock

2012

Acta Physiologica

View full text Add to dashboard Cite

The aim of this review is to describe the conceptual steps contributing to our current knowledge of purinergic signalling and to consider its involvement in the physiology and pathophysiology of the lower urinary tract. The voiding reflex involves ATP released as a cotransmitter with acetylcholine from parasympathetic nerves supplying the bladder and ATP released from urothelial cells during bladder distension to initiate the voiding reflex via P2X3 receptors on suburothelial low threshold sensory nerve fibres. This mechanosensory transduction pathway also participates, via high threshold sensory nerve fibres, in the initiation of pain in bladder and ureter. Treatment of prostate and bladder cancer with ATP is effective against the primary tumours in animal models and human cell lines, via P2X5 and P2X7 receptors, and also improves the systemic symptoms associated with advanced malignancy. Acupuncture is widely used for the treatment of urinary disorders, and a purinergic hypothesis is discussed for the underlying mechanism.

show abstract

Evaluation of the Invasive Potential of Superficial Bladder Cancer by Adenosine Triphosphate Measurement

Cited by 5 publications

References 11 publications

Purinergic signalling and cancer

Purinergic signalling and cancer

Unmasking the Metabolite Signature of Bladder Cancer: A Systematic Review

Purinergic signalling in the lower urinary tract

Contact Info

Product

Resources

About